Neuromyelitis Optica - 18 Studies Found
| Enrolling by invitation |
: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders :
|
| NOT_YET_RECRUITING |
: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA� During Pregnancy : : 2025-08-02 : Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed.No study drug will be administered. |
| NOT_YET_RECRUITING |
: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders : : 2025-08-02 : Inebilizumab: 300mg IV on Day1 and Day 15.The first dose of inelizumab is given during IVMP. |
| Completed |
: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD : Neuromyelitis Optica : 2025-08-02 : NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladd |
| Completed |
: Pediatric NMOSD Observational Study : Neuromyelitis Optica : 2025-08-02 |
| Completed |
: In Vitro Study of the Biological and Immunological Activity of Imotopes� Candidates on Blood Cells of Patients With Stabilized NMO : Neuromyelitis Optica : 2025-08-02 : The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interv |
| COMPLETED |
: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) : Neuromyelitis Optica Spectrum Disorder : 2025-08-02 : IV, once every 12 weeks (Q12W) |
| COMPLETED |
: BLAZE-Limiting Approach in NMOSD : Neuromyelitis Optica Spectrum Disorders (NMOSD) : 2025-08-02 : Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks |